UPDATED: Takeda slammed with surprise PhIII failure on 'breakthrough' blood cancer drug, imploding launch plans
One of Takeda’s “breakthrough” drugs has hit a snag.
In the Phase III PANTHER study, pevonedistat — which works by inhibiting the NEDD8-activating enzyme — failed the primary endpoint of event-free survival. And it’s prompting an evaluation of the entire clinical program.
Patients were given either a combination of pevonedistat and the chemotherapy azacitidine, or azacitidine alone.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,400+ biopharma pros reading Endpoints daily — and it's free.